Ascentage Pharma Group International (AAPG) Receivables (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Receivables for 3 consecutive years, with $35.9 million as the latest value for Q4 2025.
- For Q4 2025, Receivables rose 188.58% year-over-year to $35.9 million; the TTM value through Dec 2025 reached $35.9 million, up 188.58%, while the annual FY2025 figure was $35.4 million, 189.42% up from the prior year.
- Receivables hit $35.9 million in Q4 2025 for Ascentage Pharma Group International, up from $12.4 million in the prior quarter.
- Across five years, Receivables topped out at $35.9 million in Q4 2025 and bottomed at $12.4 million in Q4 2024.
- Average Receivables over 3 years is $23.2 million, with a median of $21.2 million recorded in 2023.
- Year-over-year, Receivables plummeted 41.33% in 2024 and then surged 188.58% in 2025.
- Ascentage Pharma Group International's Receivables stood at $21.2 million in 2023, then tumbled by 41.33% to $12.4 million in 2024, then skyrocketed by 188.58% to $35.9 million in 2025.
- According to Business Quant data, Receivables over the past three periods came in at $35.9 million, $12.4 million, and $21.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.